Get the Stockscreener App
2.02
5.16%
-0.11
After Hours:
2.09
0.07
+3.47%
Ensysce Biosciences Inc stock is traded at $2.02, with a volume of 37,800.
It is down -5.16% in the last 24 hours and down -16.53% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$2.13
Open:
$2.07
24h Volume:
37,800
Relative Volume:
0.02
Market Cap:
$4.82M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.6711
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
-2.42%
1M Performance:
-16.53%
6M Performance:
-75.06%
1Y Performance:
-75.31%
1-Day Range:
$2.02
$2.1199
1-Week Range:
$2.02
$2.15
52-Week Range:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.02 | 4.82M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 71.5% - Defense World
Leading Pain Experts Reveal New Opioid Abuse Prevention Technology at World's Largest Pain Conference - Stock Titan
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences (NASDAQ:ENSC) Trading 1.7% Higher – Here’s What Happened - Defense World
ensysce biosciences appoints baker tilly as new auditor By Investing.com - Investing.com South Africa
ensysce biosciences appoints baker tilly as new auditor - Investing.com
Ensysce Flat on Receiving Grant - Baystreet.ca
Ensysce Biosciences secures additional $5.3M NIDA grant - Investing.com Australia
Ensysce Biosciences secures additional $5.3M NIDA grant By Investing.com - Investing.com Canada
Ensysce Biosciences (ENSC) Secures $5.3M Grant to Advance Opioid Development | ENSC Stock News - GuruFocus
Revolutionary Opioid With Built-in Overdose Protection Secures $5.3M NIH Grant After FDA Breakthrough Status - Stock Titan
Ensysce Biosciences (NASDAQ:ENSC) Raised to Hold at Wall Street Zen - Defense World
When (ENSC) Moves Investors should Listen - news.stocktradersdaily.com
Where are the Opportunities in (ENSC) - news.stocktradersdaily.com
Zacks Small Cap Analysts Boost Earnings Estimates for ENSC - Defense World
Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ensysce Biosciences Advances in Pain Relief Innovation - TipRanks
Revolutionary Opioid Treatment Proves Overdose-Proof in Clinical Trials, Secures Key Patent - Stock Titan
Ensysce Biosciences Bolsters Management Team with Regulatory Expert - Stock Titan
Head-To-Head Contrast: CV Sciences (OTCMKTS:CVSI) and Ensysce Biosciences (NASDAQ:ENSC) - Defense World
(ENSC) Trading Signals - news.stocktradersdaily.com
Ensysce Biosciences (ENSC) to Release Earnings on Friday - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules - ACCESS Newswire
Ensysce Biosciences Inc (ENSC) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Ensysce Biosciences Secures $2.2M Funding Boost: Key Details on TAAP/MPAR Program Advancement - Stock Titan
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Ensysce Biosciences announces exercise of warrants for $2.2M gross proceeds - MSN
For Array Technologies Inc [ARRY], Analyst sees a rise to $7. What next? - dbtnews.com
Ensysce Biosciences (ENSC) Stock Surges on Patent News - GuruFocus
Ensysce Biosciences (ENSC) Secures $2.2 Million Through Warrant Exercise - GuruFocus
Ensysce Biosciences to raise $2.2 million through warrant exercise By Investing.com - Investing.com Canada
Ensysce Biosciences secures patent for OUD treatment By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Doubles In One Trading SessionHere's Why - AOL.com
Ensysce Biosciences to raise $2.2 million through warrant exercise - Investing.com Australia
Ensysce Biosciences Inc’s Shares Reel: -58.79% Quarterly Revenue Decline Amid 5.62M Market Cap - investchronicle.com
Dropbox Inc: Weathering Stock Market Storms with 7.92B Market Cap - investchronicle.com
Nuvation Bio Inc Inc. (NUVB) Price Performance: A Technical Analysis Perspective - investchronicle.com
Ensysce Biosciences Raises Fresh $2.2M Capital: H.C. Wainwright Backs Strategic Warrant Deal - Stock Titan
Sabre Corp (SABR) Stock: From Low to High in 52 Weeks - investchronicle.com
Analysts Are Recommending Ensysce Biosciences Inc (ENSC) As A Buy Candidate - Marketing Sentinel
Ensysce Biosciences Inc (NASDAQ:ENSC) stock: You might be surprised - uspostnews.com
Amentum Holdings Inc (AMTM) Shares Are Down -4.43% YTD - Marketing Sentinel
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views - Benzinga
The Psychology of Altria Group Inc Inc. (MO) Price Performance: Understanding Market Sentiment - investchronicle.com
Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval - Stocks Telegraph
The Psychology of Metsera Inc Inc. (MTSR) Price Performance: Understanding Market Sentiment - investchronicle.com
(ENSC) Technical Data - news.stocktradersdaily.com
Safety Shot Inc Inc. (SHOT) Price Performance: A Technical Analysis Perspective - investchronicle.com
Ensysce (ENSC) Advances PF614-MPAR in Overdose Protection Trial - GuruFocus
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):